Mark For: CERECOR™ trademark registration is intended to cover the categories of
Research | OneLook Acronym Finder |
Serial Number | 88424870 |
Mark Literal Elements | CERECOR |
Mark Drawing Type | 4 - STANDARD CHARACTER MARK |
Mark Type | TRADEMARK |
Register | PRINCIPAL |
Current Location | INTENT TO USE SECTION 2020-05-27 |
Basis | 1(b) |
Class Status | ACTIVE |
Primary US Classes |
|
Primary International Class |
|
Filed Use | No |
Current Use | No |
Intent To Use | Yes |
Filed ITU | Yes |
44D Filed | No |
44E Current | No |
66A Current | No |
Current Basis | No |
No Basis | No |
Attorney Name | Devon E. White |
Attorney Docket Number | 029492.029 |
Law Office Assigned | L70 |
Employee Name | BUTLER, MIDGE FAE |
2019-05-10 | Application Filed |
2019-09-05 | Location: PUBLICATION AND ISSUE SECTION |
2019-10-08 | Published |
2019-10-08 | Published for Opposition |
2019-10-08 | Status: Live/Pending |
2019-10-25 | Transaction Date |
2020-05-27 | Location: INTENT TO USE SECTION |
2020-06-03 | Status: A first request for extension of time to file a Statement of Use has been granted. |
Party: | Cerecor Inc. |
Address | 373 Iverness Parkway Englewood, COLORADO UNITED STATES 80112 |
Legal Entity Type | Corporation |
Legal Entity State | DELAWARE |
Drawing | JPEG | 2019-05-10 |
TEAS RF New Application | MULTI | 2019-05-10 |
XSearch Search Summary | XML | 2019-07-25 |
Priority Action | XML | 2019-08-01 |
Response to Office Action | XML | 2019-08-30 |
Amendment and Mail Process Complete | MULTI | 2019-08-31 |
TRAM Snapshot of App at Pub for Oppostn | MULTI | 2019-09-03 |
Notice of Publication | XML | 2019-09-18 |
Notification Of Notice of Publication | XML | 2019-09-18 |
OG Publication Confirmation | APPLICATION/XML | 2019-10-08 |
Notice of Allowance | APPLICATION/XML | 2019-12-03 |
Change Address or Representation Form | XML | 2020-04-28 |
Amendment and Mail Process Complete | APPLICATION/XML,IMAGE/JPEG | 2020-05-28 |
Change Address or Representation Form | XML | 2020-06-02 |
TEAS Withdrawal of Attorney | APPLICATION/XML | 2020-06-02 |
Extension of Time to File SOU | APPLICATION/XML | 2020-06-03 |
ITU Extension Approval | APPLICATION/XML | 2020-06-05 |
ITU Unit Action | MULTI | 2020-06-05 |
IC 005. US 006 018 044 046 051 052. G & S: Pharmaceutical preparations for the prevention and treatment of disorders and diseases in or affecting the central nervous system; Pharmaceutical preparations for the treatment of the brain, central nervous system, and psychiatric and neurological diseases and disorders; Pharmaceutical preparations and substances for the prevention and treatment of major depressive disorder, mood disorder, psychosis, anxiety, epilepsy, sclerosis, porphyries, stroke, Huntington's disease, insomnia, Parkinson's disease, cognitive impairment; Pharmaceutical preparations for the treatment of ectoparasites, such as head lice; Steroids; Pharmaceutical preparations containing prednisolone for the prevention and treatment of disorders of the nervous system, the immune system, the cardio-vascular system, the metabolic system, the respiratory system, the musculoskeletal system, the genitourinary system; Pharmaceutical preparations containing prednisolone for the treatment of inflammatory disorders; Pharmaceutical preparations containing prednisolone for use in dermatology, oncology, hematology and in tissue and organ transplantation, in ophthalmology and for gastroenterological disorders; Medical delivery apparatus, namely, a valved holding chamber sold empty for use with metered dose inhalers; Cephalosporins; Antibiotics; Pharmaceutical preparations for the treatment of reflux, esophagitis, GERD (Gastro-Esophageal Reflux Disease), dyspepsia, heartburn, acid regurgitation, pyrosis, epigastric pain, irritative cough and dysphonia; Oral modified release, extended release, and/or sustained release pharmaceutical preparations for the drug carbinoxamine, a pharmaceutically acceptable salt thereof and/or carbinoxamine polistirex, intended for the treatment of seasonal and perennial allergic rhinitis, and other approved uses; Vitamin, mineral and fluoride preparations for human medical or nutritional uses; Nutritional preparation in the nature of nutritional supplement containing vitamins and fluoride; Pharmaceutical products and treatments for pediatric onset and rare and orphan disorders, namely, oral formulation of D-galactose for the treatment of phosphoglucomutase 1 (PGM1) deficiency (PGM1-CDG), oral formulation of D-mannose for the treatment of Mannose Phosphate Isomerase (MPI) deficiency (MPI-CDG), oral formulation of L-fucose for the treatment of Leukocyte Adhesion Deficiency Type II (LADII) (SLC35C1-CDG), nucleotide prodrug for the treatment of Deoxyguanosine Kinase (DGUOK) deficiency; Pharmaceutical products and treatments for pediatric onset and rare and orphan disorders, namely, oral formulations for the treatment of congenital disorders of glycosylation; Pharmaceutical products and treatments for pediatric onset and rare and orphan disorders, namely, oral nucleotide replacements for the treatment of Myelodysplastic Syndromes; Pharmaceutical preparations and substances for the treatment of neurogenic orthostatic hypotension (nOH) associated with neurodegenerative diseases such as Parkinson's Disease, Multiple Systems Atrophy, and Pure Autonomic Failure; Transmembrane AMPA receptor regulatory proteins (TARPs) for use as anticonvulsant agents and to modulate neurotransmission in patients with epilepsy; Oral neuro-selective adjunctive medications; Selective kappa opioid receptor (KOR) antagonist for the treatment of major depressive disorder (MDD) and for substance use disorders
International Codes: | 5 |
U.S. Codes: | 006,018,044,046,051,052 |
Type Code | Type |
---|---|
GS0051 | Pharmaceutical preparations for the prevention and treatment of disorders and diseases in or affecting the central nervous system; Pharmaceutical preparations for the treatment of the brain, central nervous system, and psychiatric and neurological diseases and disorders; Pharmaceutical preparations and substances for the prevention and treatment of major depressive disorder, mood disorder, psychosis, anxiety, epilepsy, sclerosis, porphyries, stroke, Huntington's disease, insomnia, Parkinson's disease, cognitive impairment; Pharmaceutical preparations for the treatment of ectoparasites, such as head lice; Steroids; Pharmaceutical preparations containing prednisolone for the prevention and treatment of disorders of the nervous system, the immune system, the cardio-vascular system, the metabolic system, the respiratory system, the musculoskeletal system, the genitourinary system; Pharmaceutical preparations containing prednisolone for the treatment of inflammatory disorders; Pharmaceutical preparations containing prednisolone for use in dermatology, oncology, hematology and in tissue and organ transplantation, in ophthalmology and for gastroenterological disorders; Medical delivery apparatus, namely, a valved holding chamber sold empty for use with metered dose inhalers; Cephalosporins; Antibiotics; Pharmaceutical preparations for the treatment of reflux, esophagitis, GERD (Gastro-Esophageal Reflux Disease), dyspepsia, heartburn, acid regurgitation, pyrosis, epigastric pain, irritative cough and dysphonia; Oral modified release, extended release, and/or sustained release pharmaceutical preparations for the drug carbinoxamine, a pharmaceutically acceptable salt thereof and/or carbinoxamine polistirex, intended for the treatment of seasonal and perennial allergic rhinitis, and other approved uses; Vitamin, mineral and fluoride preparations for human medical or nutritional uses; Nutritional preparation in the nature of nutritional supplement containing vitamins and fluoride; Pharmaceutical products and treatments for pediatric onset and rare and orphan disorders, namely, oral formulation of D-galactose for the treatment of phosphoglucomutase 1 (PGM1) deficiency (PGM1-CDG), oral formulation of D-mannose for the treatment of Mannose Phosphate Isomerase (MPI) deficiency (MPI-CDG), oral formulation of L-fucose for the treatment of Leukocyte Adhesion Deficiency Type II (LADII) (SLC35C1-CDG), nucleotide prodrug for the treatment of Deoxyguanosine Kinase (DGUOK) deficiency; Pharmaceutical products and treatments for pediatric onset and rare and orphan disorders, namely, oral formulations for the treatment of congenital disorders of glycosylation; Pharmaceutical products and treatments for pediatric onset and rare and orphan disorders, namely, oral nucleotide replacements for the treatment of Myelodysplastic Syndromes; Pharmaceutical preparations and substances for the treatment of neurogenic orthostatic hypotension (nOH) associated with neurodegenerative diseases such as Parkinson's Disease, Multiple Systems Atrophy, and Pure Autonomic Failure; Transmembrane AMPA receptor regulatory proteins (TARPs) for use as anticonvulsant agents and to modulate neurotransmission in patients with epilepsy; Oral neuro-selective adjunctive medications; Selective kappa opioid receptor (KOR) antagonist for the treatment of major depressive disorder (MDD) and for substance use disorders |
Description | Date | Proceeding Number |
---|---|---|
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | 2020-06-05 | |
TEAS EXTENSION RECEIVED | 2020-06-03 | |
EXTENSION 1 GRANTED | 2020-06-03 | 98765 |
EXTENSION 1 FILED | 2020-06-03 | 98765 |
WITHDRAWAL OF ATTORNEY GRANTED | 2020-06-02 | |
TEAS WITHDRAWAL OF ATTORNEY RECEIVED | 2020-06-02 | |
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | 2020-06-02 | |
TEAS CHANGE OF OWNER ADDRESS RECEIVED | 2020-06-02 | |
TEAS CHANGE OF CORRESPONDENCE RECEIVED | 2020-06-02 | |
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | 2020-06-02 | |
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED | 2020-06-02 | 88888 |
CASE ASSIGNED TO INTENT TO USE PARALEGAL | 2020-05-27 | 71034 |
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED | 2020-05-27 | 71034 |
TEAS WITHDRAWAL OF ATTORNEY RECEIVED-FIRM RETAINS | 2020-04-28 | |
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | 2020-04-28 | |
TEAS CHANGE OF OWNER ADDRESS RECEIVED | 2020-04-28 | |
TEAS CHANGE OF CORRESPONDENCE RECEIVED | 2020-04-28 | |
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | 2020-04-28 | |
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED | 2020-04-28 | 88888 |
NOA E-MAILED - SOU REQUIRED FROM APPLICANT | 2019-12-03 | |
PUBLISHED FOR OPPOSITION | 2019-10-08 | |
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | 2019-10-08 | |
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | 2019-09-18 | |
ASSIGNED TO LIE | 2019-09-05 | 70138 |
APPROVED FOR PUB - PRINCIPAL REGISTER | 2019-09-02 | |
TEAS/EMAIL CORRESPONDENCE ENTERED | 2019-08-30 | 88889 |
TEAS RESPONSE TO OFFICE ACTION RECEIVED | 2019-08-30 | |
CORRESPONDENCE RECEIVED IN LAW OFFICE | 2019-08-30 | 88889 |
PRIORITY ACTION WRITTEN | 2019-08-01 | 68788 |
PRIORITY ACTION E-MAILED | 2019-08-01 | 6326 |
NOTIFICATION OF PRIORITY ACTION E-MAILED | 2019-08-01 | 6326 |
ASSIGNED TO EXAMINER | 2019-07-25 | 68788 |
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED IN TRAM | 2019-05-25 | |
NEW APPLICATION ENTERED IN TRAM | 2019-05-14 |
uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.
While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.
All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.